GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013842)
◆英語タイトル:GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013842
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:181
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
GlaxoSmithKline Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
GlaxoSmithKline Plc, Medical Equipment, Deal Details 17
Venture Financing 17
SetPoint Medical Raises USD30 Million in Series D Financing 17
Saluda Medical Raises USD39.4 Million in Series D Financing 19
Progyny Raises Additional USD10 Million in Series B Financing 20
SetPoint Medical Raises Funds through Venture Financing 21
CVRx Raises USD57.7 Million in Series G Financing 23
Cala Health Raises USD18 Million in Series A Financing Round 25
Setpoint Medical Raises Additional USD15 Million in Series C Venture Financing 26
Avhana Health Raises USD0.7 Million in Seed Financing 28
Progyny Raises Additional Funds through Venture Financing 29
ZappRx Raises USD5.6 Million in Series A Financing 30
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 31
ZappRx Raises US$2 Million In Seed Financing 32
Setpoint Medical Raises US$27 Million In Venture Financing 33
Health XL Raises Funds Through Venture Financing 34
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 35
SR One Plans To Invest In Biotechnology Company 36
IlluminOss Medical Raises US$28 Million In Series C Financing 37
Auxogyn Raises US$18 Million In Series B Financing 39
SpringLeaf Therapeutics Secures Additional US$4 Million In Series B Financing 40
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 41
HTG Molecular USD0.5 Million in Second Tranche of Series D Financing 42
Partnerships 43
GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 43
GlaxoSmithKline May Form Joint Venture with Qualcomm 44
Propeller Health Expands Agreement with GlaxoSmithKline 45
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 46
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 47
Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 48
AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 49
KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 50
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 51
Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 52
Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 53
Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 54
Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 55
Imperial College London, King’s College London, University College London, Medical Research Council And GSK Form Joint Venture 56
Insulet Enters Into Distribution Agreement With GlaxoSmithKline 58
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 59
Equity Offering 60
Response Genetics Completes Private Placement Of Shares For US$9 Million 60
Debt Offering 61
GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 61
GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 62
Asset Transactions 63
Sinclair IS Pharma Acquires Atlean From Stiefel Labs 63
Acquisition 64
United Therapeutics May Sell Itself 64
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 65
Teleflex Acquires Semprus BioSciences For Up To US$80 Million 66
GlaxoSmithKline Plc – Key Competitors 68
GlaxoSmithKline Plc – Key Employees 69
GlaxoSmithKline Plc – Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Joint Venture 82
Recent Developments 84
Strategy And Business Planning 84
Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 84
May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company 85
Apr 18, 2016: GSK opens new state of the art respiratory manufacturing facility in Ware, UK 86
Apr 04, 2016: Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery 87
Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund 88
Financial Announcements 89
Oct 25, 2017: GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER 89
Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 101
Apr 26, 2017: GSK delivers another quarter of continued progress 107
Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 110
Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 126
Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016 132
Apr 27, 2016: GSK Announces First quarter 2016 147
Feb 03, 2016: GSK Announces Full year and Fourth Quarter 2015 Results 151
Corporate Communications 153
Nov 08, 2017: Patrick Vallance, President, R&D, GSK to become UK Government’s Chief Scientific Adviser 153
Nov 08, 2017: Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK 154
Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 155
Jul 21, 2017: GSK announces Board and Committee changes 156
Jun 19, 2017: GSK confirms start date for Luke Miels 157
Apr 04, 2017: GSK responds to Cyclone Debbie 158
Jan 20, 2017: Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK 159
Jan 19, 2017: Abbas Hussain to leave GSK 160
Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 161
Dec 19, 2016: GSK announces Board changes 162
Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 163
Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 164
Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award 165
Jun 14, 2016: GlaxoSmithKline: Executive Director Change 166
May 27, 2016: GlaxoSmithKline Announces Board and Committee changes 167
Mar 31, 2016: GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries 168
Mar 17, 2016: Sir Andrew Witty to retire from GSK in March 2017 169
Mar 17, 2016: GlaxoSmithKline: Directorate changes 170
Mar 04, 2016: GSK names winners of 2015 Discovery Fast Track Challenge 171
Legal and Regulatory 172
Jan 20, 2016: Scientists Indicted For Allegedly Stealing Biopharmaceutical Trade Secrets 172
Product News 173
May 30, 2016: ImaBiotech to conduct Pilot Study with GSK to assess ImaBiotech’s Multimaging Technology 173
Mar 14, 2016: Magnetic resonance imaging reveals the complementary effects of decongestant and Breathe Right Nasal Strips on internal nasal anatomy 174
03/07/2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients 175
Other Significant Developments 176
Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 176
Oct 10, 2016: BIOASTER, bioMerieux, ESPCI, GSK, Hospices Civils de Lyon and Sanofi join forces against sepsis 177
Aug 24, 2016: Nanologica enters into research collaboration with GSK 179
Jul 27, 2016: GSK announces significant new investment in UK manufacturing network 180
Appendix 181
Methodology 181
About GlobalData 181
Contact Us 181
Disclaimer 181

List of Tables
GlaxoSmithKline Plc, Medical Equipment, Key Facts, 2016 2
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
GlaxoSmithKline Plc, Deals By Market, 2011 to YTD 2017 11
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
SetPoint Medical Raises USD30 Million in Series D Financing 17
Saluda Medical Raises USD39.4 Million in Series D Financing 19
Progyny Raises Additional USD10 Million in Series B Financing 20
SetPoint Medical Raises Funds through Venture Financing 21
CVRx Raises USD57.7 Million in Series G Financing 23
Cala Health Raises USD18 Million in Series A Financing Round 25
Setpoint Medical Raises Additional USD15 Million in Series C Venture Financing 26
Avhana Health Raises USD0.7 Million in Seed Financing 28
Progyny Raises Additional Funds through Venture Financing 29
ZappRx Raises USD5.6 Million in Series A Financing 30
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 31
ZappRx Raises US$2 Million In Seed Financing 32
Setpoint Medical Raises US$27 Million In Venture Financing 33
Health XL Raises Funds Through Venture Financing 34
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 35
SR One Plans To Invest In Biotechnology Company 36
IlluminOss Medical Raises US$28 Million In Series C Financing 37
Auxogyn Raises US$18 Million In Series B Financing 39
SpringLeaf Therapeutics Secures Additional US$4 Million In Series B Financing 40
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 41
HTG Molecular USD0.5 Million in Second Tranche of Series D Financing 42
GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 43
GlaxoSmithKline May Form Joint Venture with Qualcomm 44
Propeller Health Expands Agreement with GlaxoSmithKline 45
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 46
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 47
Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 48
AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 49
KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 50
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 51
Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 52
Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 53
Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 54
Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 55
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 56
Insulet Enters Into Distribution Agreement With GlaxoSmithKline 58
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 59
Response Genetics Completes Private Placement Of Shares For US$9 Million 60
GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 61
GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 62
Sinclair IS Pharma Acquires Atlean From Stiefel Labs 63
United Therapeutics May Sell Itself 64
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 65
Teleflex Acquires Semprus BioSciences For Up To US$80 Million 66
GlaxoSmithKline Plc, Key Competitors 68
GlaxoSmithKline Plc, Key Employees 69
GlaxoSmithKline Plc, Other Locations 70
GlaxoSmithKline Plc, Subsidiaries 70
GlaxoSmithKline Plc, Joint Venture 82

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析(GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆